### üß† Neurology: Amyotrophic Lateral Sclerosis (ALS) Diagnosis

#### ‚úÖ True Statements
1. **Amyotrophic lateral sclerosis (ALS)** is a **neurodegenerative motor neuron disease** that causes **progressive weakness**, **lower motor neuron signs** such as **atrophy** and **fasciculation**, and **upper motor neuron signs** such as **hyperreflexia** and **plantar extensor response**.
2. **ALS** often begins as isolated **extremity weakness** or **bulbar weakness** (including **dysphagia** and **dysarthria**) but spreads to other regions and causes **early death**.
3. Diagnosis of **ALS** requires the presence of **both upper and lower motor neuron signs** along with **electromyographic (EMG)** and **nerve conduction study (NCS)** evidence of **lower motor neuron involvement** in at least **two anatomic regions** for **probable ALS** or **more than two regions** for **definite ALS**.
4. **Riluzole**, **edaravone**, and **sodium phenylbutyrate‚Äìtaurursodiol** may offer **modest benefits** in **survival** and **functional decline** in **ALS**.
5. **Noninvasive ventilation**, when indicated in **ALS**, can improve **life expectancy**.

#### üí¨ Extra
3. The anatomic regions used for ALS diagnostic classification are **bulbar**, **cervical**, **thoracic**, and **lumbar**.

#### üè∑Ô∏è Tags
#Neurology #AmbulatoryCare #ALS #MotorNeuronDisease #Neurodegeneration

#### üìö Reference
Goutman SA, Hardiman O, Al-Chalabi A, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. *Lancet Neurol*. 2022;21:480-493. PMID: 35334233 doi:10.1016/S1474-4422(21)00465-8

#### üÜî Question ID
NRMCQ24038

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Neurology ‚Äî Neuromuscular Disorders, Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **ALS** is characterized by **upper motor neuron signs** (including **hyperreflexia**, **spasticity**, and **extensor plantar response**), **lower motor neuron signs** (including **atrophy** and **fasciculations**), and the **absence of sensory deficits**.
2. **Frontotemporal dementia** occurs in approximately **20% of patients** with **ALS**.
3. **Oculomotor palsy**, **incontinence**, and **tremor** are atypical features in **ALS**.
4. Diagnosis of **ALS** requires **clinical evidence** of both **upper and lower motor neuron signs** and **EMG/NCS evidence** of lower motor neuron signs in at least **two regions** for **probable ALS** or **more than two regions** for **definite ALS**.
5. Evaluation of suspected **ALS** must include **brain and cervical spinal imaging** and **laboratory testing** to exclude **cervical cord compression**, **vitamin B12 deficiency**, **copper deficiency**, **Lyme disease**, **HIV infection**, **hyperparathyroidism**, and **thyrotoxicosis**.
6. **Multifocal motor neuropathy** is a treatable ALS mimic characterized by **severe weakness with minimal atrophy**, **absence of upper motor neuron signs**, and **EMG/NCS evidence** of **motor conduction block**.
7. Supportive care in **ALS** should involve **multidisciplinary management**.
8. **Riluzole** (a **glutamate release blocker**), **edaravone** (a **free radical scavenger**), and **sodium phenylbutyrate‚Äìtaurursodiol** (a **combined modulator of neuronal cell death**) are **FDA-approved treatments** for **ALS**.
9. **Nutritional support**, including **percutaneous endoscopic gastrostomy (PEG)**, may benefit patients with **ALS**.
10. **Pseudobulbar affect** in **ALS** can be treated with **dextromethorphan‚Äìquinidine**.
11. Prognosis and care goals in **ALS** should be discussed **early in the disease course** to avoid unwanted diagnostic and therapeutic measures.

#### üí¨ Extra
2. **Frontotemporal dementia** associated with ALS can present with behavioral or language changes.
5. The exclusion of mimicking conditions helps prevent misdiagnosis and delays in appropriate care.

#### üè∑Ô∏è Tags
#ALS #FrontotemporalDementia #MotorNeuronDisease #NeuromuscularDisorders #Neurodegeneration

---

#### üîä Supplemental Videos

<figure>
  <video controls src="Dysarthria.mp4"></video>
  <figcaption>
    <strong>Dysarthria.</strong> This video is used with permission from the Michael S. Gordon Center for Simulation and Innovation in Medical Education, University of Miami Miller School of Medicine, Miami, FL. https://gordoncenter.miami.edu
  </figcaption>
</figure>

<figure>
  <video controls src="Extensor Plantar Response.mp4"></video>
  <figcaption>
    <strong>Extensor Plantar Response.</strong> This video is used with permission from the Michael S. Gordon Center for Simulation and Innovation in Medical Education, University of Miami Miller School of Medicine, Miami, FL. https://gordoncenter.miami.edu/
  </figcaption>
</figure>

<figure>
  <video controls src="Fasciculations.mp4"></video>
  <figcaption>
    <strong>Fasciculations.</strong> This video is used with permission from the Michael S. Gordon Center for Simulation and Innovation in Medical Education, University of Miami Miller School of Medicine, Miami, FL. https://gordoncenter.miami.edu
  </figcaption>
</figure>
